Cancer statistics: Breast cancer in situ
暂无分享,去创建一个
A. Jemal | B. Kohler | E. Ward | C. DeSantis | O. Brawley | C. Lin | J. Kramer | T. Gansler | Elizabeth E. Ward | Elizabeth M. Ward | Chun Chieh Lin
[1] P. Trott,et al. International Classification of Diseases for Oncology , 1977 .
[2] S J Schnitt,et al. Interobserver Reproducibility in the Diagnosis of Ductal Proliferative Breast Lesions Using Standardized Criteria , 1992, The American journal of surgical pathology.
[3] Eusebi,et al. Long-term follow-up of in situ carcinoma of the breast. , 1994, Seminars in diagnostic pathology.
[4] E. Feuer,et al. Permutation tests for joinpoint regression with applications to cancer rates. , 2000, Statistics in medicine.
[5] Hyune-Ju Kim,et al. Kim H-J, Fay MP, Feuer EJ, Midthune DN, ‘ Permutation tests for joinpoint regression with applications to cancer rates’. Statistics in Medicine 2000 19:335–351 , 2001 .
[6] T. Rebbeck,et al. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. , 2001, American journal of clinical pathology.
[7] W. P. Evans,et al. American Cancer Society Guidelines for Breast Cancer Screening: Update 2003 , 2003, CA: a cancer journal for clinicians.
[8] D. Carter,et al. Family History of Breast and Ovarian Cancer and the Risk of Breast Carcinoma in situ , 2003, Breast Cancer Research and Treatment.
[9] W. Dupont,et al. The natural history of low‐grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long‐term follow‐up , 2005, Cancer.
[10] G. Colditz,et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy , 2005, Cancer.
[11] Bircan Erbas,et al. The natural history of ductal carcinoma in situ of the breast: a review , 2006, Breast Cancer Research and Treatment.
[12] R. Severson,et al. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] R. Collins,et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.
[14] S. Joslyn. Ductal Carcinoma in Situ: Trends in Geographic, Temporal, and Demographic Patterns of Care and Survival , 2006, The breast journal.
[15] K. Malone,et al. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988‐2001 , 2006, Cancer.
[16] Eric J Feuer,et al. The decrease in breast-cancer incidence in 2003 in the United States. , 2007, The New England journal of medicine.
[17] D. Miglioretti,et al. Association between Breast Density and Subsequent Breast Cancer Following Treatment for Ductal Carcinoma In situ , 2007, Cancer Epidemiology Biomarkers & Prevention.
[18] M. Yaffe,et al. American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007, CA: a cancer journal for clinicians.
[19] Jun Yao,et al. Regulation of in situ to invasive breast carcinoma transition. , 2008, Cancer cell.
[20] T. Tuttle,et al. Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Elmore,et al. Communication between patients and providers and informed decision making. , 2010, Journal of the National Cancer Institute. Monographs.
[22] R. Kane,et al. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. , 2010, Journal of the National Cancer Institute.
[23] P. Ganz. Quality-of-life issues in patients with ductal carcinoma in situ. , 2010, Journal of the National Cancer Institute. Monographs.
[24] K. Kerlikowske,et al. Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Allred,et al. Ductal carcinoma in situ: terminology, classification, and natural history. , 2010, Journal of the National Cancer Institute. Monographs.
[26] R. Peto,et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. , 2010, Journal of the National Cancer Institute. Monographs.
[27] M. Silverstein,et al. Choosing treatment for patients with ductal carcinoma in situ: fine tuning the University of Southern California/Van Nuys Prognostic Index. , 2010, Journal of the National Cancer Institute. Monographs.
[28] J. Costantino,et al. The impact of systemic therapy following ductal carcinoma in situ. , 2010, Journal of the National Cancer Institute. Monographs.
[29] W. McCaskill-Stevens,et al. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. , 2010, Journal of the National Cancer Institute. Monographs.
[30] Edi Brogi,et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] E. Hwang,et al. The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. , 2010, Journal of the National Cancer Institute. Monographs.
[32] F. O'Malley,et al. Lobular neoplasia: morphology, biological potential and management in core biopsies , 2010, Modern Pathology.
[33] R. Kane,et al. Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ. , 2010, Journal of the National Cancer Institute. Monographs.
[34] C. Lawton,et al. Local Excision Alone Without Irradiation for Ductal Carcinoma In Situ of the Breast: A Trial of the Eastern Cooperative Oncology Group , 2010 .
[35] K. Polyak,et al. The microenvironment in breast cancer progression: biology and implications for treatment , 2011, Breast Cancer Research.
[36] L. Bernstein,et al. Disparities in Reconstruction Rates after Mastectomy for Ductal Carcinoma in Situ (DCIS): Patterns of Care and Factors Associated with the Use of Breast Reconstruction for DCIS Compared with Invasive Cancer , 2011, Annals of Surgical Oncology.
[37] Narasimhan P. Agaram,et al. Atypical ductal hyperplasia: interobserver and intraobserver variability , 2011, Modern Pathology.
[38] C. D’Este,et al. Patient Perception , Preference and Participation Knowledge , satisfaction with information , decisional conflict and psychological morbidity amongst women diagnosed with ductal carcinoma in situ ( DCIS ) § , 2011 .
[39] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[40] R. Kane,et al. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis , 2011, Breast Cancer Research and Treatment.
[41] T. Julian,et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.
[42] K. Bland. William Hunter Harridge Lecture: Contemporary management of pre-invasive and early breast cancer. , 2011, American journal of surgery.
[43] J. Cuzick,et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.
[44] H. Kuerer,et al. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review , 2011, Journal of Cancer.
[45] Karen A Gelmon,et al. Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.
[46] J. Thigpen. Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor–Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24 , 2012 .
[47] T. Eberlein. Radiation Therapy for Ductal Carcinoma In Situ: A Decision Analysis , 2012 .
[48] J. Ockene,et al. Effects of menopausal hormone therapy on ductal carcinoma in situ of the breast , 2013, Breast Cancer Research and Treatment.
[49] S. Fletcher,et al. Ten-year risk of diagnostic mammograms and invasive breast procedures after breast-conserving surgery for DCIS. , 2012, Journal of the National Cancer Institute.
[50] J. Elmore,et al. Challenges in ductal carcinoma in situ risk communication and decision‐making , 2012, CA: a cancer journal for clinicians.
[51] J. Elmore,et al. Ductal carcinoma in situ (DCIS): raising signposts on an ill-marked treatment path. , 2012, Journal of the National Cancer Institute.
[52] V. Beral,et al. Comparison of the effects of genetic and environmental risk factors on in situ and invasive ductal breast cancer , 2012, International journal of cancer.
[53] Sunil R. Lakhani,et al. WHO classification of tumours of the breast , 2012 .
[54] T. Julian,et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] J. Dixon,et al. Endocrine Therapy in DCIS: How Do We Proceed? , 2012, The breast journal.
[56] T. Sørlie,et al. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study , 2013, BMC Cancer.
[57] George W. Sledge,et al. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.
[58] H. Bartelink,et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] W. McCaskill-Stevens,et al. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43 , 2013, Breast Cancer Research and Treatment.
[60] I. Ellis,et al. Lobular Neoplasia of the Breast Revisited With Emphasis on the Role of E-Cadherin Immunohistochemistry , 2013, The American journal of surgical pathology.
[61] J. Cuzick,et al. Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Andrew H. Beck,et al. Mammographic density and risk of breast cancer by age and tumor characteristics , 2013, Breast Cancer Research.
[63] Sook-Young Woo,et al. Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast , 2013, The British journal of surgery.
[64] C. Mathers,et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .
[65] A. Recht. Are the randomized trials of radiation therapy for ductal carcinoma in situ still relevant? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] R. Jagsi,et al. Social and Clinical Determinants of Contralateral Prophylactic Mastectomy. , 2014, JAMA surgery.
[67] Julian Peto,et al. Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast , 2014, PLoS genetics.
[68] L. Holmberg,et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Harvey,et al. Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice? , 2014, World journal of clinical oncology.
[70] Derek C. Radisky,et al. Understanding the Premalignant Potential of Atypical Hyperplasia through Its Natural History: A Longitudinal Cohort Study , 2014, Cancer Prevention Research.
[71] J. Cuzick,et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial , 2014, The Lancet.
[72] Joann G Elmore,et al. Mammographic performance in a population-based screening program: before, during, and after the transition from screen-film to full-field digital mammography. , 2014, Radiology.
[73] Karthik Devarajan,et al. Identifying a Highly-Aggressive DCIS Subgroup by Studying Intra-Individual DCIS Heterogeneity among Invasive Breast Cancer Patients , 2014, PloS one.
[74] D. Winchester,et al. Breast conserving therapy for DCIS—Does size matter? , 2014, Journal of surgical oncology.
[75] P. Porter,et al. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55–74 years of age , 2014, Breast Cancer Research and Treatment.
[76] S. Shak,et al. Abstract S5-04: A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation , 2015 .
[77] Karla Kerlikowske,et al. Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium , 2015, Cancer.
[78] S. Shak,et al. A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone , 2015, Breast Cancer Research and Treatment.
[79] L. Hartmann,et al. Atypical hyperplasia of the breast--risk assessment and management options. , 2015, The New England journal of medicine.
[80] Barbara L. Smith,et al. RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] David L. Page,et al. Continued observation of the natural history of low-grade ductal carcinoma in situ reaffirms proclivity for local recurrence even after more than 30 years of follow up , 2014, Modern Pathology.
[82] L. Norton,et al. Current management of lesions associated with an increased risk of breast cancer , 2015, Nature Reviews Clinical Oncology.
[83] M. Broder,et al. The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12‐gene DCIS score™ result , 2015, Journal of surgical oncology.
[84] T. Julian,et al. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] J. Elmore,et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. , 2015, JAMA.
[86] A. Chagpar,et al. Epidemiology of Ductal Carcinoma In Situ , 2015 .